OrthoPediatrics Corp.
KIDSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeOrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic. The company carries a $639.7M market cap, placing it firmly in the small-cap category. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.
Market Cap
$639.7M
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-34.51
EPS (TTM)
$-1.68
EPS (Fwd)
$-0.71
ROE
-11.4%
ROA
-2.8%
Cash
$45.9M
Total Debt
$111.2M
Free CF
$3.2M
52W Change
44.5%
Annual Financials
Cash vs Debt
Where KIDS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KIDS finished 11.83% above its 150-day moving average ($19.70) and 14.68% above its 200-day moving average ($19.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KIDS overbought or oversold?
At the October 20, 2026 close, KIDS's RSI(14) was 43.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $45.9M in cash, though total debt stands at $111.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $3.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -11.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $122.3M (2022) to $236.3M (2025), reflecting a 93% increase over the period.
As with any equity investment, KIDS carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence OrthoPediatrics Corp.'s trajectory.